CVS HEALTH Corp 8-K, filed Nov 6, 2020
CVS HEALTH Corp (CVS)
About this 8-K
CVS HEALTH Corp filed this 8-K on November 6, 2020, reporting on events of November 5, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): | November 6, 2020 ( |

(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code: | ( |
| Former name or former address, if changed since last report: | N/A |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company | |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |
Section 5 – Corporate Governance and Management
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Larry J. Merlo’s Retirement as President and Chief Executive Officer and as a Director
On November 6, 2020, CVS Health Corporation (“CVS Health”) announced that Larry J. Merlo, currently the President and Chief Executive Officer and a member of the Board of Directors of CVS Health (the “Board”), notified CVS Health on November 5, 2020 of his intention to retire effective May 31, 2021 and, in connection therewith, step down from the offices of President and Chief Executive Officer effective February 1, 2021. Thereafter, Mr. Merlo will continue to be employed at CVS Health to assist the new President and Chief Executive Officer on transition matters until his retirement from CVS Health on May 31, 2021. Mr. Merlo has also informed CVS Health that he will not seek re-election to the Board at CVS Health’s 2021 annual meeting of stockholders. In connection with this transition, Mr. Merlo has agreed to waive any and all rights that he may have to terminate his employment with CVS Health under the terms of his Amended and Restated Employment Agreement, dated as of December 22, 2008 and amended as of December 21, 2012, in connection with the planned transition effective February 1, 2021. Mr. Merlo’s decision to retire and not to seek re-election to the Board is not the result of any dispute or disagreement with CVS Health. Mr. Merlo’s retirement comes after a 40-year career with CVS Health, including serving as Chief Executive Officer since March 2011 and as President and a member of the Board since May 2010.
Appointment of Karen S. Lynch as President and Chief Executive Officer and Director
On November 5, 2020, the Board appointed Karen S. Lynch to serve as President and Chief Executive Officer of CVS Health, and as a Director, both effective February 1, 2021. Upon the effectiveness of her appointment to the Board, Ms. Lynch will join the Executive Committee of the Board.
In connection with Ms. Lynch’s appointment as a Director, the Board also approved an increase in the size of the Board from 13 directors to 14 directors effective on the date of her appointment.
Ms. Lynch, age 57, is currently Executive Vice President, CVS Health and President, Aetna. Ms. Lynch has held this position since 2018 following CVS Health’s acquisition of Aetna Inc. (“Aetna”) and has been President of Aetna since 2015. Prior to that, Ms. Lynch was Executive Vice President, Local and Regional Businesses of Aetna from February 2013 through December 2014. Ms. Lynch is also a member of the board of directors of U.S. Bancorp, a banking and financial services company. Ms. Lynch is a graduate of Boston College and The Questrom School of Business at Boston University.
In connection with Ms. Lynch’s appointment to President and Chief Executive Officer of CVS Health, CVS Health entered into an amended and restated employment agreement with Ms. Lynch, to become effective February 1, 2021 (the “Lynch Agreement”). The Lynch Agreement sets forth, among other things, the terms of her employment as President and Chief Executive Officer of CVS Health. The Lynch Agreement has no specified term and provides that Ms. Lynch’s employment with CVS Health will be on an at-will basis. Further, pursuant to the Lynch Agreement, Ms. Lynch will receive an annualized base salary of $1.45 million and will be eligible to participate in CVS Health’s annual bonus plan with a target annual cash bonus opportunity of 200% of her base salary, effective February 1, 2021. In addition, Ms. Lynch’s target annual equity award compensation for 2021 will be $11,000,000, which will be comprised of 75% performance stock units and 25% stock options. For any equity awards granted on or following the effectiveness of the Lynch Agreement, Ms. Lynch will be treated as “retirement” eligible under the vesting and exercise terms of the applicable award agreements relating to CVS Health awards generally applicable to senior-level executives of CVS Health. Upon a qualifying termination of employment, Ms. Lynch would be entitled to a cash severance payment equal to two-times (which is increased to two-and-a-half times if the qualifying termination of employment occurs within two years following a change in control) the sum of her highest base salary in effect during the six-month period immediately prior to the date of her termination of employment and her target annual bonus opportunity for the year of her termination of employment. Ms. Lynch would also be entitled to a prorated annual bonus for the year of her termination of employment and up to 18 months of continued health and benefit plan participation at the same benefit and cost sharing level at which Ms. Lynch and her eligible dependents were participating on the date of her termination of employment.
The Lynch Agreement also provides for a Section 280G “best net” provision, which would reduce the value of any change in control payments or benefits that Ms. Lynch would be eligible to receive to the extent necessary to avoid the adverse tax consequences of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended (to the extent that the reduction would put Ms. Lynch in a better after-tax position).
Pursuant to the Lynch Agreement, Ms. Lynch also entered into a new CVS Health restrictive covenant agreement to, among other things, increase her post-employment non-competition and non-solicitation periods to 24 months following her employment with CVS Health.
There are no family relationships, as defined in Item 401 of Regulation S-K, between Ms. Lynch and any of CVS Health’s executive officers or directors or persons nominated or chosen to become a director or executive officer. Ms. Lynch has not engaged in any transaction with CVS Health during the last fiscal year, and she does not propose to engage in any transaction, that would be reportable under Item 404(a) of Regulation S-K.
Section 9 – Financial Statements and Exhibits
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The exhibits to this Current Report on Form 8-K are as follows:
INDEX TO EXHIBITS
| Exhibit | Description | |
| 99.1 | Press Release of CVS Health Corporation, dated November 6, 2020. | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CVS HEALTH CORPORATION | ||
| Date: November 6, 2020 | By: | /s/ Colleen M. McIntosh |
|
Colleen M. McIntosh | ||
| Senior Vice President, Chief Governance Officer and Corporate Secretary | ||

CVS Health Announces CEO Transition Effective February 2021
Karen
S. Lynch Named the Next President and CEO of CVS Health and Larry J. Merlo to
Retire in Spring 2021
WOONSOCKET, R.I., Nov. 6, 2020 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) today announced that its Board of Directors appointed Karen S. Lynch, currently Executive Vice President, CVS Health and President, Aetna, as the company’s next President and CEO, effective February 1, 2021. Ms. Lynch will also join the company’s Board of Directors upon assuming her new role. Larry J. Merlo will transition from the President and CEO role on February 1, 2021, after beginning his career with the company as a community pharmacist more than 40 years ago, and serving as President and CEO for a decade. Mr. Merlo will continue to serve on CVS Health’s Board of Directors until the company’s next Annual Meeting of Stockholders in May 2021, and as Strategic Advisor to assist with the transition until his retirement on May 31, 2021.
“This leadership transition comes at the right time for CVS Health. This month marks the two year anniversary as one company, with our foundation clearly established and significant positive momentum across the company,” said David W. Dorman, Chair of the Board of CVS Health Corporation. “As Larry has been transparent with us about his overall plans, we were able to put a thorough, multi-year process in place to consider and evaluate internal and external candidates. That process led to the selection of Karen Lynch. Larry’s collaboration with Karen in the coming months will ensure an effective leadership transition.”
“Karen is a seasoned health care expert who knows our business. She brings a relentless focus on the customer, a strong track record of driving growth and innovation, and proven transformational leadership, all of which positions her well for success. Our Board of Directors believes that Karen is the right leader to guide CVS Health into its next era of growth as the company continues its transformation,” Mr. Dorman continued.
“I am deeply honored to have the opportunity to succeed Larry and lead CVS Health on the next phase of our important journey to meet America’s health care needs,” said Karen S. Lynch, Executive Vice President, CVS Health and President, Aetna. “Never before has our purpose been more critical than during these unprecedented times. Together with the CVS Health leadership team and all of our colleagues, I will work to build on the strong foundation Larry has put in place to continue to make health care more accessible and affordable, driving better health outcomes for our consumers and communities. I am highly confident about our company’s future and look forward to further accelerating the value we bring to all of our stakeholders.”
| 1 |

“On behalf of CVS Health and the Board, I would like to thank Larry for his outstanding leadership and deep commitment to the company. During his tenure, CVS Health has transformed from a regional retail pharmacy into the nation’s leading diversified health services company, with over $250 billion in revenues. Larry led CVS Health’s industry-disrupting acquisition of Aetna in 2018, and strategically positioned the company’s community-based health clinics to provide integrated and holistic health care services to all Americans. In doing so, he created new ways to deliver health care through CVS Health’s unparalleled suite of assets, including a national health insurance plan provider, a pharmacy benefits manager, community-based retail pharmacies and a long-term care pharmacy services business,” said Mr. Dorman. “No discussion of Larry’s tenure would be complete without recognizing his leadership of the company’s bold decision to eliminate the sale of tobacco products from all CVS Pharmacy stores, which was widely credited with being a catalyst for the reduction in smoking levels in the U.S.”
“I am incredibly proud to have had the opportunity to lead CVS Health over the past decade as we pursue our important purpose to help people on their path to better health,” said Larry J. Merlo, President and Chief Executive Officer, CVS Health. “I am grateful to our entire CVS Health team for their dedication and hard work in helping us build a powerful, integrated health services company that will enable us to transform how health care is delivered across the country. Karen has been a key partner to me in our foundational work over the last two years, and her experience and vision will be critical in driving forward CVS Health’s journey of enhancing value for our customers as the nation’s leading health care company for years to come.”
In her current role as Executive Vice President, CVS Health and President, Aetna, and with eight years in total at Aetna, Ms. Lynch is responsible for leading the company’s strategy to deliver consumer-focused, high-value health care to the millions of people Aetna serves. She is also responsible for developing diversified enterprise health care solutions that leverage all of CVS Health’s assets. Prior to joining Aetna in 2012, she was President of Magellan Health Services, a diversified health services company, and held various senior executive positions at Cigna.
At CVS Health, Ms. Lynch had a critical leadership role in the company’s integration of Aetna, launching its first suite of transformative products and services, including the Aetna Connected Plan, powered by CVS Health, and Aetna health plans with access to all covered MinuteClinic services at no cost. Under her leadership Medicare Advantage membership grew more than three times the industry average, generating outstanding membership growth of over 30 percent in 2019. Ms. Lynch has also been instrumental in the design of the HealthHUB strategy, incorporating the HealthHUBs’ differentiated suite of services into Aetna’s offerings.
| 2 |

Ms. Lynch is consistently rated as a top innovator and influencer in the health care space and has been named to Business Insider’s Top 100 People Transforming Business for the significant role she plays in transforming businesses through innovative solutions that deliver value to customers and drive growth. From 2016 to 2020, she was named to Fortune’s Most Powerful Women in Business list. Ms. Lynch also serves on the Board of U.S. Bancorp and is the Chair of its Audit Committee.
About CVS Health
CVS Health is a different kind of health care company. We are a diversified health services company with nearly 300,000 employees united around a common purpose of helping people on their path to better health. In an increasingly connected and digital world, we are meeting people wherever they are and changing health care to meet their needs. Built on a foundation of unmatched community presence, our diversified model engages one in three Americans each year. From our innovative new services at HealthHUB locations, to transformative programs that help manage chronic conditions, we are making health care more accessible, more affordable… and simply better. Learn more about how we’re transforming health at www.cvshealth.com.
Media contact
T.J. Crawford
Vice President, External Affairs
212-457-0583
crawfordt2@aetna.com
Investor contact
Valerie Haertel
Senior Vice President, Investor Relations
401-770-4050
valerie.haertel@cvshealth.com
####
| 3 |